Early application of low-level laser may reduce the incidence of postherpetic neuralgia (PHN)

Yu-Tsung Chen, Hsiao-Han Wang, Tsung-Jen Wang, Yu-Chuan Li, Ting-Jui Chen

研究成果: 雜誌貢獻文章

4 引文 (Scopus)

摘要

BACKGROUND: Postherpetic neuralgia (PHN) is difficult to treat, and currently there are no available treatments that effectively reduce its incidence. Low-level laser therapy (LLLT) has been proposed for indirect virus deactivation in treating recurrent herpes simplex infections.

OBJECTIVE: This study seeks to investigate whether LLLT could reduce the incidence of PHN.

METHODS: We retrospectively reviewed the incidence of PHN at the first, third, and sixth months after rash outbreak in 3 groups: the acute group of patients who received LLLT during the first 5 days; the subacute group of patients who received LLLT during days 6 to 14 of the eruption; and the control group of patients who did not receive LLLT.

RESULTS: There were 48, 48, and 154 patients in the acute, subacute, and control groups, respectively. After adjusting for confounding factors, including age, sex, and use of famciclovir, the incidence of PHN was significantly lower in the acute group versus the control group after 1 month (odds ratio [OR] 0.21, P = .006, 95% confidence interval [CI] 0.068-0.632), 3 months (OR 0.112, P = .038, 95% CI 0.014-0.886), and 6 months (OR 0.123, P = .021, 95% CI 0-0.606). The subacute group only had a lower incidence (OR 0.187, P = .032, 95% CI 0.041-0.865) after 3 months when compared with the control group.

LIMITATIONS: This is a retrospective study lacking double-blind randomization, and the placebo effect may be a major concern. Lack of standardized and prospective evaluation measures is also a limitation of this study.

CONCLUSION: Applying LLLT within the first 5 days of herpes zoster eruption significantly reduced the incidence of PHN. LLLT may have the potential to prevent PHN, but further well-designed randomized controlled trials are required.
原文英語
頁(從 - 到)572-577
頁數6
期刊Journal of the American Academy of Dermatology
75
發行號3
DOIs
出版狀態已發佈 - 九月 2016

指紋

Postherpetic Neuralgia
Lasers
Incidence
Odds Ratio
Confidence Intervals
Control Groups
Placebo Effect
Herpes Simplex
Age Factors
Herpes Zoster
Random Allocation
Low-Level Light Therapy
Exanthema
Disease Outbreaks
Randomized Controlled Trials
Retrospective Studies
Viruses
Infection

引用此文

@article{f3c5c9ded81640b1864c21c0eb8795dd,
title = "Early application of low-level laser may reduce the incidence of postherpetic neuralgia (PHN)",
abstract = "BACKGROUND: Postherpetic neuralgia (PHN) is difficult to treat, and currently there are no available treatments that effectively reduce its incidence. Low-level laser therapy (LLLT) has been proposed for indirect virus deactivation in treating recurrent herpes simplex infections.OBJECTIVE: This study seeks to investigate whether LLLT could reduce the incidence of PHN.METHODS: We retrospectively reviewed the incidence of PHN at the first, third, and sixth months after rash outbreak in 3 groups: the acute group of patients who received LLLT during the first 5 days; the subacute group of patients who received LLLT during days 6 to 14 of the eruption; and the control group of patients who did not receive LLLT.RESULTS: There were 48, 48, and 154 patients in the acute, subacute, and control groups, respectively. After adjusting for confounding factors, including age, sex, and use of famciclovir, the incidence of PHN was significantly lower in the acute group versus the control group after 1 month (odds ratio [OR] 0.21, P = .006, 95{\%} confidence interval [CI] 0.068-0.632), 3 months (OR 0.112, P = .038, 95{\%} CI 0.014-0.886), and 6 months (OR 0.123, P = .021, 95{\%} CI 0-0.606). The subacute group only had a lower incidence (OR 0.187, P = .032, 95{\%} CI 0.041-0.865) after 3 months when compared with the control group.LIMITATIONS: This is a retrospective study lacking double-blind randomization, and the placebo effect may be a major concern. Lack of standardized and prospective evaluation measures is also a limitation of this study.CONCLUSION: Applying LLLT within the first 5 days of herpes zoster eruption significantly reduced the incidence of PHN. LLLT may have the potential to prevent PHN, but further well-designed randomized controlled trials are required.",
keywords = "2-Aminopurine, Adult, Case-Control Studies, Female, Follow-Up Studies, Herpes Zoster, Humans, Logistic Models, Low-Level Light Therapy, Male, Middle Aged, Neuralgia, Postherpetic, Pain Measurement, Prognosis, Reference Values, Retrospective Studies, Risk Assessment, Severity of Illness Index, Time Factors, Treatment Outcome, Comparative Study, Journal Article",
author = "Yu-Tsung Chen and Hsiao-Han Wang and Tsung-Jen Wang and Yu-Chuan Li and Ting-Jui Chen",
note = "Copyright {\circledC} 2016 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.",
year = "2016",
month = "9",
doi = "10.1016/j.jaad.2016.03.050",
language = "English",
volume = "75",
pages = "572--577",
journal = "Journal of the American Academy of Dermatology",
issn = "0190-9622",
publisher = "Mosby Inc.",
number = "3",

}

TY - JOUR

T1 - Early application of low-level laser may reduce the incidence of postherpetic neuralgia (PHN)

AU - Chen, Yu-Tsung

AU - Wang, Hsiao-Han

AU - Wang, Tsung-Jen

AU - Li, Yu-Chuan

AU - Chen, Ting-Jui

N1 - Copyright © 2016 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.

PY - 2016/9

Y1 - 2016/9

N2 - BACKGROUND: Postherpetic neuralgia (PHN) is difficult to treat, and currently there are no available treatments that effectively reduce its incidence. Low-level laser therapy (LLLT) has been proposed for indirect virus deactivation in treating recurrent herpes simplex infections.OBJECTIVE: This study seeks to investigate whether LLLT could reduce the incidence of PHN.METHODS: We retrospectively reviewed the incidence of PHN at the first, third, and sixth months after rash outbreak in 3 groups: the acute group of patients who received LLLT during the first 5 days; the subacute group of patients who received LLLT during days 6 to 14 of the eruption; and the control group of patients who did not receive LLLT.RESULTS: There were 48, 48, and 154 patients in the acute, subacute, and control groups, respectively. After adjusting for confounding factors, including age, sex, and use of famciclovir, the incidence of PHN was significantly lower in the acute group versus the control group after 1 month (odds ratio [OR] 0.21, P = .006, 95% confidence interval [CI] 0.068-0.632), 3 months (OR 0.112, P = .038, 95% CI 0.014-0.886), and 6 months (OR 0.123, P = .021, 95% CI 0-0.606). The subacute group only had a lower incidence (OR 0.187, P = .032, 95% CI 0.041-0.865) after 3 months when compared with the control group.LIMITATIONS: This is a retrospective study lacking double-blind randomization, and the placebo effect may be a major concern. Lack of standardized and prospective evaluation measures is also a limitation of this study.CONCLUSION: Applying LLLT within the first 5 days of herpes zoster eruption significantly reduced the incidence of PHN. LLLT may have the potential to prevent PHN, but further well-designed randomized controlled trials are required.

AB - BACKGROUND: Postherpetic neuralgia (PHN) is difficult to treat, and currently there are no available treatments that effectively reduce its incidence. Low-level laser therapy (LLLT) has been proposed for indirect virus deactivation in treating recurrent herpes simplex infections.OBJECTIVE: This study seeks to investigate whether LLLT could reduce the incidence of PHN.METHODS: We retrospectively reviewed the incidence of PHN at the first, third, and sixth months after rash outbreak in 3 groups: the acute group of patients who received LLLT during the first 5 days; the subacute group of patients who received LLLT during days 6 to 14 of the eruption; and the control group of patients who did not receive LLLT.RESULTS: There were 48, 48, and 154 patients in the acute, subacute, and control groups, respectively. After adjusting for confounding factors, including age, sex, and use of famciclovir, the incidence of PHN was significantly lower in the acute group versus the control group after 1 month (odds ratio [OR] 0.21, P = .006, 95% confidence interval [CI] 0.068-0.632), 3 months (OR 0.112, P = .038, 95% CI 0.014-0.886), and 6 months (OR 0.123, P = .021, 95% CI 0-0.606). The subacute group only had a lower incidence (OR 0.187, P = .032, 95% CI 0.041-0.865) after 3 months when compared with the control group.LIMITATIONS: This is a retrospective study lacking double-blind randomization, and the placebo effect may be a major concern. Lack of standardized and prospective evaluation measures is also a limitation of this study.CONCLUSION: Applying LLLT within the first 5 days of herpes zoster eruption significantly reduced the incidence of PHN. LLLT may have the potential to prevent PHN, but further well-designed randomized controlled trials are required.

KW - 2-Aminopurine

KW - Adult

KW - Case-Control Studies

KW - Female

KW - Follow-Up Studies

KW - Herpes Zoster

KW - Humans

KW - Logistic Models

KW - Low-Level Light Therapy

KW - Male

KW - Middle Aged

KW - Neuralgia, Postherpetic

KW - Pain Measurement

KW - Prognosis

KW - Reference Values

KW - Retrospective Studies

KW - Risk Assessment

KW - Severity of Illness Index

KW - Time Factors

KW - Treatment Outcome

KW - Comparative Study

KW - Journal Article

U2 - 10.1016/j.jaad.2016.03.050

DO - 10.1016/j.jaad.2016.03.050

M3 - Article

C2 - 27543213

VL - 75

SP - 572

EP - 577

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

SN - 0190-9622

IS - 3

ER -